We have previously demonstrated that CD4+ T cells reactive against a secreted myeloma protein tumor antigen can mediate protection against tumor development upon challenge with MOPC315 myeloma cells (2, 6, 7, 12). Here, LINC01194 is linked to plasma cell myeloma.